MedTrace Logo

A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma

NCT04648319 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2022-02-23

No results posted yet for this study

Summary

This is an Open-label, single-arm, multicenter Phase II pilot study to assess the efficacy and safety of BMS-936558 with stereotactic ablative radiation therapy after induction chemotherapy in cholangiocarcinoma.

Conditions

Interventions

DRUG

BMS-936558

BMS-936558 followed by 30 grays of 3 to 5 fractions of high dose SBRT followed by monthly BMS-936558 until progression

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • American University of Beirut Medical Center

    lead OTHER

Principal Investigators

  • Ali Shamseddine, MD · American University of Beirut Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-15
Primary Completion
2022-01-17
Completion
2022-01-17

Countries

  • Belgium
  • Lebanon
  • Luxembourg

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04648319 on ClinicalTrials.gov